Member Info for desamax

You say “your clueless whether the assets will materialise” would you agree the HNW investors have a good idea?

Maidit apologies,
I took the bit in your post “now that GSK
has shown there hands 737 related, “
As something announced post last Sar update, I had missed

Hi Maidit,
Where can I find the info related to GSK and SRA737?
Thanks in anticipation

Have also followed this brave ladies battle ever since she was highlighted on this forum a few years ago. I believe she is followed by a few of us on Twitter including Sareum. Thiago out to her family and friends, god bless.

Hi Laza
Thanks for that, I remember Dilly saying late last year that Sra737 was tucked away in his back pocket if needed. He later came out with the news it could be used in conjunction, while he was firmly in a nda during the takeover negotiations, strange that he mentioned sra737. I wonder who or what was behind that move. Maybe over thinking as per usual

Can anyone remember the timeline of the presentations that Dilly was on, was he presenting while his board were in deep negotiations with GSK and others? Am I right in thinking the last mention of SRA737 with atz515 was in Feb

Sorry to keep bringing this up but what is the relevance of Company G mentioned on pg 39 last paragraph?
It’s said “ six unnamed companies were interested“
A-F, Company G is mentioned under a different light, I don’t read G as a buyer.
Most probably nothing but it bugging me.

GSK & A-F = 7 still leaves unnamed party G

Mike that would explain a lot, lol

Also on April 1, 2022, Dr. Dilly met with a representative of a biopharmaceutical company, that we refer to as “Party G,” in connection with
ongoing discussions between Sierra Oncology and Party G regarding opportunities for licensing, partnership and other strategic transactions. As part of
the discussion, Dr. Dilly and the representative discussed on a preliminary basis the possibility of a business combination between Sierra Oncology and
Party G, but deferred further discussion to a future date.

6 bidders = A - F who or what was party G ? or am I not getting this right.
Anyone

TYK2 JAK1
Seeking funding and licence partners for autoimmune and/or oncology applications.
Grant and other funding for Covid-19 applications
Listed as value driver for 2022.
Hmmmmmm

Would the CTA application or even the C19 extended trial that were announced as on track to be progressed in firsts half of the year be in conclusion with any interested party? Only a few weeks before we find out.

At least this mornings SP has kept the negatives quite for a while.

https://youtu.be/VRH4qBu5zqo

RMMs post might also give you a pointer.

Hi Horse, it was posted just before from a very reliable source and got lost after the GSK takeover, cant remember where, but i made a note that reads
CB = 1,009,521
JR = 965,832
TM= 809,521
Nothing on SP
I hope this helps GLA

I’m sure I read somewhere Birch is now the largest bod holder with just over a million Tim and John now have under a million each.

Hi Nrd, GSK have Oncology, fingers and toes crossed they require SRA737 to move forward rapidly.
https://www.nature.com/articles/d42473-020-00457-6

Hopefully looking forward to the trials starting. Will GSK have a hand in this?

SRA737: A Selective Chk1 inhibitor (cancer)

During the second half of 2021 and early 2022, Sierra Oncology, Inc. (“Sierra”), the licence holder for SRA737, noted it is finalising the design of several potential clinical trials to advance its pipeline candidates, including SRA737, which could start in 2022. These trials are expected to investigate SRA737 in combination with other agents in haematologic and solid tumour indications
The dosing of the first patient with SRA737 in any new clinical trial would result in a $2.0m payment from Sierra under the amended $290m licensing deal on SRA737 between Sierra and CRT Pioneer Fund LP. Under the amended agreement, Sareum continues to be eligible to receive a 27.5% share of this and any future milestone payments as well as royalties on any future sales